bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
Intangible Assets
bluebird bio Inc
Intangible Assets Peer Comparison
Competitive Intangible Assets Analysis
Latest Figures & CAGR of Competitors
Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
bluebird bio Inc
NASDAQ:BLUE
|
Intangible Assets
$5.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Intangible Assets
$62.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
43%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Intangible Assets
$23.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Intangible Assets
$31.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
35%
|
CAGR 10-Years
9%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Intangible Assets
$834.9m
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Intangible Assets
$1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is bluebird bio Inc's Intangible Assets?
Intangible Assets
5.4m
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's Intangible Assets amounts to 5.4m USD.
What is bluebird bio Inc's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-17%
The average annual Intangible Assets growth rates for bluebird bio Inc have been -21% over the past three years , -17% over the past five years .